Trials / Completed
CompletedNCT05217355
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Medytox Korea · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBA-P01 (Botulinum toxin A) | MBA-P01 will be injected into the Glabellar line |
| DRUG | Placebo | Placebo will be injected into the Glabellar line |
Timeline
- Start date
- 2021-12-28
- Primary completion
- 2022-06-22
- Completion
- 2022-06-22
- First posted
- 2022-02-01
- Last updated
- 2023-02-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05217355. Inclusion in this directory is not an endorsement.